Idenix Seen As Unlikely to Prevail Against Gilead in HCV Patent Interference
- Christine Livoti and Anusha Kambhampaty
- Biopharm Insight
Deborah Sterling is quoted in a BioPharm Insight article about Idenix Pharmaceuticals' patent interference against Gilead Sciences. A recent decision designated Idenix as the junior party and Gilead as the senior party, placing the burden of proof in the proceeding on the former.
Sterling says, "If Idenix can prove an earlier actual reduction to practice, or an earlier conception coupled with diligence over the critical period, it could prevail."